Demo
KPTI Nasdaq· Karyopharm Therapeutics Inc.
FundamentalsNews digest Peer analysis
Login
KPTI Nasdaq· Karyopharm Therapeutics Inc.
Earnings report Q4 2023

Karyopharm Therapeutics Inc. Reports Decline in Revenue for the Latest Quarter

Segments of Revenue

Karyopharm Therapeutics Inc. reported a decline in revenue for the latest quarter. The company's product revenue, net, decreased to $112.01 million, compared to $120.45 million in the previous year's quarter. Similarly, license and other revenue also declined to $34.02 million, down from $36.63 million in the same quarter last year. Overall, the total revenue for the quarter amounted to $146.03 million, reflecting a decrease from $157.07 million in the previous year's quarter.

Strengths

Despite the decline in revenue, Karyopharm Therapeutics Inc. has demonstrated strength in maintaining a consistent level of product revenue. The company's product revenue, net, remained relatively stable at $112.01 million for the latest quarter, compared to $120.45 million in the previous year's quarter. This indicates a steady demand for their products in the market.

Challenges

The decline in revenue for Karyopharm Therapeutics Inc. raises concerns about the company's ability to generate sufficient revenue to cover its operating expenses. The total operating expenses for the latest quarter amounted to $275.57 million, exceeding the total revenue of $146.03 million. This resulted in a loss from operations of $129.54 million. The company needs to address this challenge and find ways to increase revenue or reduce expenses to achieve profitability.

Noteworthy

It is worth noting that Karyopharm Therapeutics Inc. has not paid any cash dividends on its common stock and does not expect to pay any in the foreseeable future. Additionally, the company's stock performance graph shows a comparison of the cumulative total return on an assumed investment in their common stock, indicating the historical performance of their stock compared to the NASDAQ Composite Index and the NASDAQ Biotechnology Index.

Summary

Karyopharm Therapeutics Inc. experienced a decline in revenue for the latest quarter, with both product revenue and license and other revenue decreasing compared to the previous year's quarter. However, the company demonstrated strength in maintaining a consistent level of product revenue. The challenge lies in the company's ability to generate sufficient revenue to cover its operating expenses, as evidenced by the loss from operations. Karyopharm Therapeutics Inc. should focus on strategies to increase revenue or reduce expenses to achieve profitability in the future.

Source documents

Form 10-K  filed on Feb 29, 2024
44 pages scanned

Reference data

Company financials Q4 revenue 33.7M
Analyst estimates Q4 EPS beat by 26.01%
Sign up to Fey

Get in-depth analysis on thousands of stocks for just $30/month. Cancel anytime.